Skip to main content
PMC home page
Gut logoLink to Gut
. 1991 May;32(5):462–463. doi: 10.1136/gut.32.5.462

Sulphasalazine in ulcerative colitis: in memoriam?

J Hayllar 1, I Bjarnason 1
PMCID: PMC1378915  PMID: 1674925

Full text

PDF
462

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aruoma O. I., Wasil M., Halliwell B., Hoey B. M., Butler J. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects? Biochem Pharmacol. 1987 Nov 1;36(21):3739–3742. doi: 10.1016/0006-2952(87)90028-1. [DOI] [PubMed] [Google Scholar]
  2. Austin C. A., Cann P. A., Jones T. H., Holdsworth C. D. Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis. Lancet. 1984 Apr 21;1(8382):917–918. doi: 10.1016/s0140-6736(84)91386-2. [DOI] [PubMed] [Google Scholar]
  3. Azad Khan A. K., Howes D. T., Piris J., Truelove S. C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. BARON J. H., CONNELL A. M., LENNARD-JONES J. E., JONES F. A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962 May 26;1(7239):1094–1096. doi: 10.1016/s0140-6736(62)92080-9. [DOI] [PubMed] [Google Scholar]
  5. Bachrach W. H. Sulfasalazine: I. An historical perspective. Am J Gastroenterol. 1988 May;83(5):487–496. [PubMed] [Google Scholar]
  6. Calder I. C., Funder C. C., Green C. R., Ham K. N., Tange J. D. Comparative nephrotoxicity of aspirin and phenacetin derivatives. Br Med J. 1971 Nov 27;4(5786):518–521. doi: 10.1136/bmj.4.5786.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Comer S. S., Jasin H. E. In vitro immunomodulatory effects of sulfasalazine and its metabolites. J Rheumatol. 1988 Apr;15(4):580–586. [PubMed] [Google Scholar]
  8. Das K. M., Eastwood M. A., McManus J. P., Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973 Sep 6;289(10):491–495. doi: 10.1056/NEJM197309062891001. [DOI] [PubMed] [Google Scholar]
  9. Gibson P. R., Jewell D. P. Sulphasalazine and derivatives, natural killer activity and ulcerative colitis. Clin Sci (Lond) 1985 Aug;69(2):177–184. doi: 10.1042/cs0690177. [DOI] [PubMed] [Google Scholar]
  10. Hoult J. R., Moore P. K. Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle. Br J Pharmacol. 1980 Apr;68(4):719–730. doi: 10.1111/j.1476-5381.1980.tb10865.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ireland A., Priddle J. D., Jewell D. P. Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. Clin Sci (Lond) 1990 Jan;78(1):105–111. doi: 10.1042/cs0780105. [DOI] [PubMed] [Google Scholar]
  12. Kaufmann H. J., Taubin H. L. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987 Oct;107(4):513–516. doi: 10.7326/0003-4819-107-4-513. [DOI] [PubMed] [Google Scholar]
  13. Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
  14. Lauritsen K., Laursen L. S., Bukhave K., Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology. 1988 Jul;95(1):11–17. doi: 10.1016/0016-5085(88)90284-3. [DOI] [PubMed] [Google Scholar]
  15. McConkey B. History of the development of sulphasalazine in rheumatology. Drugs. 1986;32 (Suppl 1):12–17. doi: 10.2165/00003495-198600321-00004. [DOI] [PubMed] [Google Scholar]
  16. Molin L., Stendahl O. The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis. Acta Med Scand. 1979;206(6):451–457. doi: 10.1111/j.0954-6820.1979.tb13545.x. [DOI] [PubMed] [Google Scholar]
  17. Neumann V. C., Taggart A. J., Le Gallez P., Astbury C., Hill J., Bird H. A. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J Rheumatol. 1986 Apr;13(2):285–287. [PubMed] [Google Scholar]
  18. Nielsen S. T., Beninati L., Buonato C. B. Sulfasalazine and 5-aminosalicylic acid inhibit contractile leukotriene formation. Scand J Gastroenterol. 1988 Apr;23(3):272–276. doi: 10.3109/00365528809093864. [DOI] [PubMed] [Google Scholar]
  19. Novis B. H., Korzets Z., Chen P., Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1988 May 21;296(6634):1442–1442. doi: 10.1136/bmj.296.6634.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pieniaszek H. J., Jr, Bates T. R. Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats. J Pharm Sci. 1979 Oct;68(10):1323–1325. doi: 10.1002/jps.2600681036. [DOI] [PubMed] [Google Scholar]
  21. Rasmussen S. N., Bondesen S., Hvidberg E. F., Hansen S. H., Binder V., Halskov S., Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982 Nov;83(5):1062–1070. [PubMed] [Google Scholar]
  22. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988 Jun;94(6):1383–1389. doi: 10.1016/0016-5085(88)90677-4. [DOI] [PubMed] [Google Scholar]
  23. Ruf-Ballauf W., Hofstädter F., Krentz K. Akute interstitielle Nephritis durch 5-Aminosalicylsäure? Internist (Berl) 1989 Apr;30(4):262–264. [PubMed] [Google Scholar]
  24. Sheldon P., Webb C., Grindulis K. A. Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action? Br J Rheumatol. 1988 Oct;27(5):344–349. doi: 10.1093/rheumatology/27.5.344. [DOI] [PubMed] [Google Scholar]
  25. Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol. 1988 May;83(5):497–503. [PubMed] [Google Scholar]
  26. Weiss S. J. Tissue destruction by neutrophils. N Engl J Med. 1989 Feb 9;320(6):365–376. doi: 10.1056/NEJM198902093200606. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES